BioCryst
Pharmaceuticals, Inc. BCRX today announced that the National
Institute of Allergy and Infectious Diseases (NIAID) has contracted
with BioCryst for the development of BCX4430
as a treatment for Marburg virus disease. NIAID, part of the National
Institutes of Health, has made an initial award of $5.0 million to
BioCryst. The total funding could be up to $22.0 million over five
years, if all contract options are exercised. BCX4430 is the lead
compound in BioCryst's broad-spectrum antiviral (BSAV) research program.
The goals of this contract are to file investigational new drug (IND)
applications for intravenous (i.v.) and intramuscular (i.m.) BCX4430 for
the treatment of Marburg virus disease, and to conduct an initial
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in